The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases

Current Vascular Pharmacology

Volumn 6, Issue 3, 2008, Pages 204-217

  Yu, Jingjing ^a   Weïwer, Michel ^b   Linhardt, Robert J ^a,b,c   Dordick, Jonathan S ^a,c  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^b Research Rensselaer Polytechnic Institute   (United States)

^c RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Apocynin; Cardiovascular diseases; Nicotinamide adenine dinucleotide phosphate; Oxidative stress; Reactive oxygen species; Reduced form (NADPH) oxidase

Indexed keywords

ANGIOTENSIN II; APOCYNIN; ARSENOSOBENZENE; CALMODULIN INHIBITOR; CATECHOL DERIVATIVE; CIBACRON BLUE F3GA; DIPHENYLIODONIUM SALT; DISULFIRAM; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME INHIBITOR; ESCULETIN; GLIOTOXIN; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLE; KUTKIN; LOW DENSITY LIPOPROTEIN; MEPACRINE; NITRIC OXIDE; NITROSOTHIOL DERIVATIVE; PENICILLAMINE; PYRIDINE; QUERCETIN; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR; SUPEROXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ACETOPHENONE DERIVATIVE; CARDIOTONIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL TYPE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; ENZYME STRUCTURE; ENZYME SYNTHESIS; GENOTOXICITY; HUMAN; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHAGOCYTE; POLYMERIZATION; PROTEIN ASSEMBLY; PROTEIN LIPID INTERACTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ACETOPHENONES; ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; NADPH OXIDASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 53449087924     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016108784911984     Document Type: Review

References (173)

1. Hertog MG, Feskens PC, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993; 342: 1007-11.
2. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339: 1523-26.
3. Teissedre PL, Frankel EN, Waterhouse AL, Peleg H, German JB. Inhibition of in vitro human LDL oxidation by phenolic antioxidants from grapes and wines. J Sci Food Agric 1996; 70: 55-61.
4. Serafini M, Ghiselli A, Ferro-Luzzi A. Red wine, tea and antioxidants. Lancet 1994; 344: 626.
5. Aviram M, Eias K. Dietary olive oil reduces low-density lipoprotein uptake by macrophages and decreases the susceptibility of the lipoprotein to undergo lipid peroxidation. Ann Nutr Metab 1993; 37: 75-84.
6. Fuhrman B, Lavy A, Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am J Clin Nutri 1995; 61: 549-54.
7. Fuhrman B, Buch S, Vaya J, Belinky PA, Coleman R, Hayek T, et al. Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: in vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutri 1997; 66: 267-75.
8. Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, et al. Reduced progression of atherosclerosis in apolipoprotein-E deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thrombos Vascul Biol 1997; 17: 2744-52.
9. Miura Y, Chiba T, Tomita I, Koizumi H, Miura S, Umegaki K, et al. Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. J Nutri 2001; 131: 27-32.
10. Rosenblat M, Belinky P, Vaya J, Levy R, Hayek T, Coleman R, et al. Macrophage enrichment with isoflavin glabridin inhibits NADPH oxidase-induced cell-mediated oxidation of low density lipoprotein: a possible role for protein kinase C. J Biol Chem 1999; 274: 13790-9.
11. Simons JM, Hart BA, Ip Vai Ching TRAM, Dijk H van, Labadie RP. Metabolic activation of natural phenols into selective oxidative burst antagonists by activated human neutrophils. Free Radical Bio Med 1990; 8: 251-8.
12. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Resp Cell Mol 1994; 11: 95-102.
13. Ahn J, Grun IU, Fernando LN. Antioxidant properties of natural plant extracts containing polyphenolic compounds in cooked ground beef. J Food Sci 2002; 67: 1364-9.
14. Baublis AJ, Lu C, Clydesdale FM, Decker EA. Potential of wheat-based breakfast cereals as a source of dietary antioxidants. J Am Coll Nutri 2000; 19: 308S-11S.
15. Deighton N, Stewart D, Davies HV, Gardner PT, Duthis GG, Mullen W, et al. Soft fruit as sources of dietary antioxidants. Acta Horticulture 2002; 585: 459-65.
16. Lugasi A, Dworschak E, Hovari J. Antioxidant property of polyphenolic compounds of culinary herbs and medicinal plants. Special Publication - Royal Soc of Chem 1996; 179: 372-9.
17. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
18. Holland JA, Meyer JW, Schmitt ME, Sauro MD, Johnson DK, Abdul-Karim RW, et al. Low-density lipoprotein stimulated peroxide production and endocytosis in cultured human endothelial cells: mechanisms of action. Endothelium 1997; 5: 191-207.
19. Holland JA, Johnson DK. Prevention of atherosclerosis using NADPH oxidase inhibitors. US Patent 5,902,831, 1999
20. Ximenes VFK, MPP, Rissato SR, Galhiane MS. Arch Biochem Biophys 2007; 457: 134-41.
21. Fridovich I. Oxygen toxicity: a radical explanation. J Exp Biol 1998; 201: 1203-9.
22. Schafer F, Buettner G. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radical Bio Med 2001; 30: 1191-212.
23. Lennon S, Martin S, Cotter T. Dose-dependent induction of apoptosis in human tumor cell lines by widely diverging stimuli. Cell Prolif 1991; 22: 203-14.
24. Lee Y, Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem 1999; 274(28): 19792-8.
25. Lelli J, Becks L, Dabrowska M, Hinshaw D. ATP converts necrosis to apoptosis in oxidant-injured endothelial cells. Free Radical Bio Med 1998; 25: 694-702.
26. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
27. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42: 1075-81.
28. Docampo R. In: Antioxidant mechanisms. Biochemistry and Molecular Biology of Parasites Ed, J Marr Müller M. 1995; London: Academic Press. 147-60.
29. Sies HH. Oxidative stress: introductory remarks Oxidative Stress, Ed. H. Sies. 1985; London: Academic Press Inc. 1-7.
30. Babior BM, Curnutte JT, McMurrich BJ. The particulate superoxide-forming system from human neutrophils. Properties of the system and further evidence supporting its participation in the respiratory burst. J Clin Invest 1976; 58: 989-96.
31. Babior BM. Oxygen-dependent microbial killing by phagocytes. N Engl J Med 1978; 298: 659-68.
32. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. Third Edition Ed. 1998; Oxford Science Publications. 33-4.
33. Melov S, Doctrow SR, Schneider JA, Haberson J, Patel M, Coskun PE, et al. Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J Neurosci 2001; 21: 8348-58.
34. Krotz F, Sohn HY, Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 2004; 24: 1988-96.
35. 2, a necessary evil for cell signaling. Science 2006; 312: 1882-3.
36. Kettle AJ, Winterbourn CC. Myeloperoxidase: A key regulator of neutrophil oxidant production. Redox Rep 1997; 3: 3-13.
37. Klebanoff SJ. Myeloperoxidase. Proc Assoc Am Phys 1999; 111(5): 383-9.
38. Zipfel M, Carmine TC, Gerber C, Niethammer D, Bruchelt G. Evidence for the activation of myeloperoxidase by f-Meth-Leu-Phe prior to its release from neutrophil granulocytes. Biochem Biophys Res Commun 1997; 232: 209-12.
39. Harrison JE, Shultz J. Studies on the chlorinating activity of myeloperoxidase. J Biol Chem 1976; 251: 1371-4.
40. Samuni A, Black CDV, Krishna CM, Malech HL, Bernstein EF, Russo A. Hydroxyl radical production by stimulated neutrophils reappraised. J Biol Chem 1988; 263: 13797-801.
41. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454-6.
42. Thomson L, Trujillo M, Telleri R, Radi R. Kinetics of cytochrome c2+ oxidation by peroxynitrite: implications for superoxide measurements in nitric oxide-producing biological systems. Arch Biochem Biophys 1995; 319: 491-7.
43. Fridovich I. Oxygen toxicity: a radical explanation. J Exp Biol 1998; 201: 1203-9.
44. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4.
45. Bredt DS, Snyder SH. Nitric oxide: A physiologic messenger molecule. Annu Rev Biochem 1994; 63:175-95.
46. Harald HH, Schmidt W, Walter U. NO at work. Cell 1994; 78: 919-25.
47. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmaco Rev 1991; 43: 109-42.
48. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 1992; 298: 431-7.
49. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998; 92: 3007-17.
50. Babior BM. NADPH oxidase: an update. Blood 1999; 93: 1464-76.
51. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003; 15: 247-54.
52. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002; 9: 387-99.
53. Rey FE, Li XC, Carretero OA, Garvin JL, Pagano PJ. Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation: role of gp91(phox). Circulation 2002; 106: 2497-502.
54. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Treads Pharmacol Sci 2003; 24: 471-8.
55. Kojda G., Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43: 562-71.
56. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997; 17: 2479-88.
57. Pou S, Pou WS, Bredt DS, Snyder SH, Rosen GM. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem 1992; 267: 24173-6.
58. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol 1997; 20: II-11-7.
59. O'Donnell VB, Freeman BA. Interactions between nitric oxide and lipid oxidation pathways: implications for vascular disease. Circ Res 2001; 88 12-21.
60. Pieper GM, Langenstroe P, Siebeneich W. Diabetic-induced endothelial dysfunction in rat aorta: role of hydroxyl radicals. Cardiovasc Res 1997; 34: 145-56.
61. Wedgwood S, Dettman RW, Black SM. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 2001; 281: L1058-67.
62. Lomax KJ, Leto TL, Nunoi H, Gallin JI, Malech HL. Minor errors in two published sequences. Science 1989; 246: 987.
63. Lomax KJ, Leto TL, Nunoi H, Gallin JI, Malech HL. Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease. Science 1989; 245: 409-12.
64. Rotrosen D, Yeung CL, Leto TL, Malech HL, Kwong CH. Cytochrome b558: the flavin-binding component of the phagocyte NADPH oxidase. Science 1992; 256: 1459-62.
65. Segal AW, West I, Wientjes F, Nugent JH, Chavan AJ, Haley B, et al. Cytochrome b-245 is a flavocytochrome containing FAD and the NADPH-binding site of the microbicidal oxidase of phagocytes. Biochem J 1992; 284: 781-8.
66. Volpp BD, Nauseef WM, Clark RA. Two cytosolic neutrophil oxidase components absent in autosomal chronic granulomatous disease. Science 1988; 242: 1295-7.
67. Geiszt M, Leto TL. The Nox Family of NAD(P)H Oxidases: Host Defense and Beyond. J Biol Chem 2004; 279: 51715-8.
68. Leto TL, Adams AG, de Mendez I. Assembly of the phagocyte NADPH oxidase: binding of Src homology 3 domains to prolinerich targets. Proc Natl Acad Sci USA 1994; 91: 10650-4.
69. Sumimoto H, Kage Y, Nunoi H, Sasaki H, Nose T, Fukumaki Y, et al. Role of Src homology 3 domains in assembly and activation of the phagocyte NADPH oxidase. Proc Natl Acad Sci U S A 1994; 91: 5345-9.
70. Regier DS, Greene DG, Sergeant S, Jesaitis AJ, McPhail LC. Phosphorylation of p22phox is mediated by phospholipase D-dependent and -independent mechanisms. Correlation of NADPH oxidase activity and p22phox phosphorylation. J Biol Chem 2000; 275: 28406-12.
71. Regier DS, Waite KA, Wallin R, McPhail LC. A phosphatidic acid-activated protein kinase and conventional protein kinase C isoforms phosphorylate p22(phox), an NADPH oxidase component. J Biol Chem 1999; 274: 36601-8.
72. Groemping Y, Rittinger K. Activation and assembly of the NADPH oxidase: a structural perspective. Biochem J 2005; 386: 401-16.
73. Kanai F, Liu H, Field SJ, Akbary H, Matsuo T, Brown GE, et al. The PX domains of p47phox and p40phox bind to lipid products of PI(3)K. Nat Cell Biol 2001; 3: 675-8.
74. Groemping Y, Lapouge K, Smerdon SJ, Rittinger K. Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell 2003; 113: 343-55.
75. Lapouge K, Smith SJ, Groemping Y, Rittinger K. Architecture of the p40-p47-p67phox complex in the resting state of the NADPH oxidase. A central role for p67phox. J Biol Chem 2002; 277: 10121-8.
76. Brown GE, Stewart MQ, Liu H, Ha VL, Yaffe MB. A novel assay system implicates PtdIns(3,4)P(2), PtdIns(3)P, and PKC delta in intracellular production of reactive oxygen species by the NADPH oxidase. Mol Cell 2003; 11: 35-47.
77. Jiang F, Drummond GR, Dusting GJ. Suppression of oxidative stress in the endothelium and vascular wall. Endothelium 2004; 11: 79-88.
78. Whitin JC, Ryan DH, Cohen HJ. Graded responses of human neutrophils induced by serum-treated zymosan. Blood 1985; 66:1182-8.
79. Williams LT, Snyderman R, Pike MC, Lefkowitz RJ. Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes. Proc Natl Acad Sci 1977; 74: 1204-8.
80. Ogle JD, Noel JG, Sramkoski RM, Ogle CK, Alexander JW. Phagocytosis of opsonized fluorescent microspheres by human neutrophils. A two-color flow cytometric method for the determination of attachment and ingestion. J Immunol Methods 1988; 115: 17-29.
81. Weinbaum DL, Sullivan JA, Mandell GL. Receptors for concanavalin A cluster at the front of polarized neutrophils. Nature 1980; 286: 725-7.
82. Schnitzler N, Schweizer K, Podbielski A, Haase G, Spellerberg B, Holland R, et al. Activation of granulocytes by phorbol-12-myristate -14-acetate (PMA) enhances phagocytosis of Streptococcus pyogenes. Adv Exp Med Biol 1997; 418: 897-902.
83. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004; 4: 181-9.
84. Fontayne A, Dang PM, Gougerot-Pocidalo MA, El-Benna J. Phosphorylation of p47phox sites by PKC alpha, beta II, delta, and zeta: effect on binding to p22phox and on NADPH oxidase activation. Biochemistry 2002; 41: 7743-50.
85. Hoyal CR, Gutierrez A, Young BM, Catz SD, Lin JH, Tsichlis PN, et al. Modulation of p47PHOX activity by site-specific phosphorylation: Akt-dependent activation of the NADPH oxidase. Proc Natl Acad Sci USA 2003; 100: 5130-5.
86. Yuzawa S, Ogura K, Horiuchi M, Suzuki NN, Fujioka Y, Kataoka, M, et al. Solution structure of the tandem Src homology 3 domains of p47phox in an autoinhibited form. J Biol Chem 2004; 279: 29752-60.
87. Ago T, Kuribayashi F, Hiroaki H, Takeya R, Ito T, Kohda D, et al. Phosphorylation of p47phox directs phox homology domain from SH3 domain toward phosphoinositides, leading to phagocyte NADPH oxidase activation. Proc Natl Acad Sci U S A 2003; 100: 4474-9.
88. Han CH, Freeman JL, Lee T, Motalebi SA, Lambeth JD. Regulation of the neutrophil respiratory burst oxidase. Identification of an activation domain in p67(phox). J Biol Chem 1998; 273: 16663-8.
89. Sumimoto H, Hata K, Mizuki K, Ito T, Kage Y, Sakaki Y, et al. Assembly and activation of the phagocyte NADPH oxidase. Specific interaction of the N-terminal Src homology 3 domain of p47phox with p22phox is required for activation of the NADPH oxidase. J Biol Chem 1996; 271: 22152-8.
90. DeLeo FR, Yu L, Burritt JB, Loetterle LR, Bond CW, Jesaitis AJ, et al. Mapping sites of interaction of p47-phox and flavocytochrome b with random-sequence peptide phage display libraries. Proc Natl Acad Sci USA 1995; 92: 7110-4.
91. Brandes RP, Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 2005; 65: 16-27.
92. McPhail LC. SH3-dependent assembly of the phagocyte NADPH oxidase. J Exp Med 1994; 180: 2011-5.
93. Leusen JH, Bolscher BG, Hilarius PM, Weening RS, Kaulfersch W, Seger RA, et al. 156Pro - >Gln substitution in the light chain of cytochrome b558 of the human NADPH oxidase (p22-phox) leads to defective translocation of the cytosolic proteins p47-phox and p67-phox. J Exp Med 1994; 180: 2329-34.
94. Dahan I, Issaeva I, Gorzalczany Y, Sigal N, Hirshberg M, Pick E. Mapping of functional domains in the p22(phox) subunit of flavocytochrome b(559) participating in the assembly of the NADPH oxidase complex by "peptide walking". J Biol Chem 2002; 277: 8421-32.
95. Aviram M, Rosenblat M, Etzioni A, Levy R. Activation of NADPH oxidase required for macrophage-mediated oxidation of low-density lipoprotein. Metabolism 1996; 45: 1069-79.
96. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 2000; 87: 26-32.
97. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA 1997; 94: 14483-8.
98. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-9.
99. Li WG, Miller FJ Jr, Zhang HJ, Spitz DR, Oberley LW, Weintraub NL.H(2)O(2)-induced O(2) production by a non-phagocytic NAD(P)H oxidase causes oxidant injury. J Biol Chem 2001; 276: 29251-6.
100. Mueller CF, Laude K, McNally JS, Harrison DG. ATVB in focus: redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol 2005; 25: 274-8.
101. Barchowsky A, Klei LR, Dudek EJ, Swartz HM, James PE. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radical Bio Med 2000; 27: 1405-12.
102. Holland JA, Meyer JW, Chang MM, O'Donnell RW, Johnson DK, Ziegler LM. Thrombin-stimulated reactive oxygen species production in cultured human endothelial cells. Endothelium 1998; 6: 113-21.
103. Holland JA, O'Donnell RW, Chang M-M, Johnson DK, Ziegler LM. Endothelial cell oxidant production: effect of NADPH oxidase inhibitors. Endothelium 2000; 7: 109-19.
104. Meyer JW, Holland JA, Ziegler LM, Chang M-M, Beebe G, Schmitt ME. Identification of a functional leukocyte-type NADPH oxidase in human endothelial cells: a potential atherogenic source of reactive oxygen species. Endothelium 1999; 7: 11-22.
105. Weber C, Erl W, Pietsch A, Strobel M, Ziegler-Heitbrock HW, Weber PC. Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. Arterioscler Thromb 1994; 14: 1665-73.
106. Bayraktutan U, Draper N, Lang D, Shah AM. Expression of functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells. Cardiovasc Res 1998; 38: 256-62.
107. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OT. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol 1996; 271: H1626-34.
108. Li JM, Shah AM. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 2002; 277: 19952-60.
109. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996; 271: 23317-21.
110. Kalinina N, Agrotis A, Tararak E, Antropova Y, Kanellakis P, Ilyinskaya O, et al. Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2002; 22: 2037-43.
111. Lassègue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, et al. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001; 88: 888-94.
112. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, et al. Expression of a functionally active gp91phox-containing neutrophiltype NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 2002; 90: 1205-13.
113. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004; 109: 227-33.
114. Sorescu D, Weiss D, Lassègue B, Clempus RE, Szöcs K, Sorescu GP, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002; 105: 1429-35.
115. Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, Brandes RP. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 2004; 279: 45935-41.
116. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 2001; 108: 1513-22.
117. Lavigne MC, Malech HL, Holland SM, Leto TL. Genetic demonstration of p47phox-dependent superoxide anion production in murine vascular smooth muscle cells. Circulation 2001; 104: 79-84.
118. Botond B, Clark RA, Steger K, Krause K-H. Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem 2003; 278: 3510-3.
119. Cheng G, Lambeth JD. NOXO1, regulation of lipid binding, localization, and activation of Nox1 by the Phox homology (PX) domain. J Biol Chem 2004; 279: 4737-42.
120. Ambasta RK, Schreiber JG, Janiszewski M, Busse R, Brandes RP. Noxa1 is a central component of the smooth muscle NADPH oxidase in mice. Free Radic Biol Med 2006; 41: 193-201.
121. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003; 285: R277-97.
122. Frey RS, Rahman A, Kefer JC, Minshall RD, Malik AB. PKCzeta regulates TNF-alpha-induced activation of NADPH oxidase in endothelial cells. Circ Res 2002; 90: 1012-9.
123. Stocker R, Keaney Jr. JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-478.
124. Touyz RM, Yao G, Schiffrin EL. c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 981-7.
125. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002; 40: 511-5.
126. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem 2003; 278: 12094-100.
127. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91: 406-13.
128. Rikitake YL, JK. Rho GTPases, Statins, and Nitric Oxide. Circ Res 2005; 97: 1232-5.
129. Baykal Y, Yilmaz MI, Celik T, Gok F, Rehber H, Akay C, et al. Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress. J Hypertens 2003; 21: 1207-11.
130. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Bräsen JH, Skatchkov M, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99: 2027-33.
131. Cayatte AJ, Rupin A, Oliver-Krasinski J, Maitland K, Sansilvestri-Morel P, Boussard MF, et al. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler Thromb Vasc Biol 2001; 21: 1577-84.
132. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 2001; 88: 947-53.
133. Al-Mehdi AB, Zhao G, Dodia C, Tozawa K, Costa K, Muzykantov V, et al. Endothelial NADPH oxidase as the source of oxidants in lungs exposed to ischemia or high K+. Circ Res 1998; 83: 730-7.
134. Ikeda Y, Young LH, Scalia R, Ross CR, Lefer AM. PR-39, a proline/ arginine-rich antimicrobial peptide, exerts cardioprotective effects in myocardial ischemia-reperfusion. Cardiovasc Res 2001; 49: 69-77.
135. Shi J, Ross CR, Leto TL, Blecha F. PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox. Proc Natl Acad Sci USA 1996; 93: 6014-8.
136. Chan YR, Zanetti M, Gennaro R, Gallo RL. Anti-microbial activity and cell binding are controlled by sequence determinants in the anti-microbial peptide PR-39. J Invest Dermatol 2001; 116: 230-5.
137. Tanaka K, Fujimoto Y, Suzuki M, Suzuki Y, Ohtake T, Saito H, et al. PI3-kinase p85alpha is a target molecule of proline-rich antimicrobial peptide to suppress proliferation of ras-transformed cells. Jpn J Cancer Res 2001; 92: 959-67.
138. Dusting GJ, Selemidis S, Jiang F. Mechanisms for suppressing NADPH oxidase in the vascular wall. Mem Inst Oswaldo Cruz 2005; 100 Suppl 1: 97-103.
139. Dominguez XA, Pugliese OA. A chemical study of Mammillaria runyoni: The isolation of acetovanillone and a new triterpenoid, mamillarol. Planta Med 1967; 15: 401-403.
140. Kokubun T, Harborne B. Phytoalexin induction in the sapwood of plants of the Maloideae (Rosaceae): biphenols or dibenzofurans. Phytochemistry 1995; 40: 1649-54.
141. Muhleneck U, Barz W. Cytochrome -P450-dependent formation of α-hydroxy-acetovanillone from acetovanillone in Solanum khasianum. Phytochemistry 1997; 44(5): 865-7.
142. Pyysalo T, Honkanen E. The influence of heat on the aroma of cloudberries (Rubus chamaemorus L.) Z. Lebensm. Unters.-Forsch 1977; 163: 25-30.
143. 11 by some naturally occurring acetophenones and plant extracts from the shrub Salsola tuberculatiformis. Planta Med 1993; 59: 139-43.
144. Chen CL, Chang HM. Aromatic acids produced during degradation of lignin in spruce wood by phanerochaete Chrysosporium. Holzforschung 1982; 36: 3-9.
145. Pelmont J, Tournesac C, Mliki A, Barelle M, Beguin C. A new bacterial alcohol dehydrogenase active on degraded lignin and several low molecular weight aromatic compounds. FEMS Micorbiol Lett 1989; 57: 109-13.
146. Wood HC. A study of Apcynunm cannabinum. J Am Med Assoc 1904; 43: 1953-7.
147. Finnemore H. The constituents of Canadian hemp; Part I: Apocynin. J Chem Soc 1908; 93: 1513-20.
148. Basu K, Dasgupta B, Bhattacharya SK, Debnath PK. Chemistry and pharmocology of apocynin, isolated from Picrorhiza kurroa Royle ex Benth. Curr Sci 1971; 40: 603-4.
149. Krishnamurthy A. The wealth of India. Vol VIII 1969; New Delhi: Publication and Information Directorate, Council of Scientific and Industrial Research.
150. Nishikawa M, Kudo M, Kakemizu N, Ikeda H, Okubo T. Role of superoxide anions in airway hyperresponsiveness induced by cigarette smoke in conscious guinea pigs. Lung 1996; 174: 279-89.
151. Antoniotti S, Santhanam L, Ahuja D, Hogg MG, Dordick JS. Structural diversity of peroxidase-catalyzed oxidation products of omethoxyphenols. Org Lett 2004; 6: 1975-8.
152. Suzuki Y, Wang W, Vu TH, Raffin TA. Effect of NADPH oxidase inhibition on endothelial cell ELAM-1 mRNA expression. Biochem Biophys Res Commun 1992; 184: 1339-143.
153. Stolk J, Rossie W, Dijkman JH. Apocynin improves the efficacy of secretory leukocyte protease inhibitor in experimental emphysema. Am J Respir Crit Care Med 1994; 150: 1628-31.
154. Hart BA, Simons JM. Metabolic activation of phenols by stimulated neutrophils: a concept for a selective type of anti-inflammatory drug. Biotechnol Ther 1992; 3: 119-35.
155. Müller AA, Reiter SA, Heider KG, Wagner H. Plant-derived acetophenones with antiasthmatic and anti-inflammatory properties: inhibitory effects on chemotaxis, right angle light scatter and actin polymerization of polymorphonuclear granulocytes. Planta Med 1999; 65: 590-4.
156. Johnson DK, Schillinger KJ, Kwait DM, Hughes CV, McNamara EJ, Ishmael F, et al. Inhibition of NADPH oxidase activation in endothelial cells by ortho-methoxy-substituted catechols. Endothelium 2002; 9: 191-203.
157. Jiang F, Dusting GJ. Natural phenolic compounds as cardiovascular therapeutics: potential role of their anti-inflammatory effects. Curr Vasc Pharmacol 2003; 1: 135-56.
158. Cathcart MK, McNally AK, Morel DW, Chisolm GM. Superoxide anion participation in human monocyte-mediated oxidation of low density lipoprotein and conversion of low density lipoprotein to a cytotoxin. J Immunol 1989; 142: 1963-9.
159. Crawford DW, Blankenhorn DH. Arterial wall oxgenation, oxyradicals, and atherosclerosis Atherosclerosis 1991; 89: 97-108.
160. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: E85-90.
161. Hessler JR, Morel DW, Lewis LJ, Chisolm GM. Lipoprotein oxidation and lipoprotein-induced cytotoxicity Arteriosclerosis 1983; 3: 215-22.
162. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-92.
163. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546-51.
164. Kimpe SJD, Änggård EE, Carrier MJ. Reactive oxygen species regulate macrophage scavenger receptor type I, but not type II, in the human monocytic cell line THP-1. Mol Pharmacol 1998; 53: 1076-82.
165. Wedgwood S, Dettman RW, Black SM. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 2001; 281: L1058-67.
166. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001; 38: 1107-11.
167. Wu R, Millette E, Wu L, de Champlain J. Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J Hypertens 2001; 19: 741-8.
168. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, et al. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 2002; 39: 269-74.
169. Virdis A, Ghiadoni L, Cardinal H, Favilla S, Duranti P, Birindelli R, et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol 2001; 38: 1106-15.
170. Gajewska R, Ganowiak Z, Grzybowski J, Radecki A, Wrzesniowska K. Analysis of an industrial smoke preparation. Bromat Chem Toksykol 1981; XIV: 3-4.
171. Pfuhler S, Stehrer-Schmid P, Dorsch W, Wagner H, Wolf HU. Investigation of genotoxic effects of the anti-asthmatic and antiinflammatory drugs apocynin and acetosyringenin in the Salmonella typhimurium mutagenicity assay and the SCE-test with human lymphocytes. Phytomedicine 1995; 4: 319-22.
172. Peters EA, Hiltermann JT, Stolk J. Effect of apocynin on ozoneinduced airway hyperresponsiveness to methacholine in asthmatics. Free Radic Biol Med 2001; 31: 1442-7.
173. Simons JM. Immonomodulation by Picrorhiza kurroa: basis for its ethnomedical use? 1989; Universiteit Utrecht.